BioSpace20h
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
BioSpace17h
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...
BioSpace18h
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
BioSpace19h
Roche Buys Poseida for up to $1.5B, Leaning Into Off-the-Shelf CAR T
The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...
BioSpace21h
AstraZeneca’s Truqap Redeems Itself with Phase III Prostate Cancer Win
Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...